{"title":"激素受体和HER2在乳腺鳞状细胞癌中的预后分析：使用SEER数据库的匹配研究。","authors":"Miao Wang, Kehua Hu, Yanping Gao, Xiaowan Guo, Jie Li, Yaoxiong Xia, Hui Qiu, Qiuji Wu","doi":"10.1016/j.clbc.2025.04.015","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To determine the prognostic differences between breast squamous cell carcinoma (BSCC) and breast infiltrating ductal adenocarcinoma (BIDC) by receptor subtype.</p><p><strong>Materials and methods: </strong>We extracted data from the SEER Registry for adult women diagnosed with BSCC and BIDC from 2010 to 2020. Kaplan-Meier curves and log-rank tests assessed survival differences. Propensity score matching analysis (PSM) was used to match subjects with similar characteristics. Cox proportional hazard regression models identified survival predictors.</p><p><strong>Results: </strong>BSCC patients were older (> 60 years: 60.6% vs. 52.4%, P = .037), had higher TNBC incidence (64.0% vs. 12.2%, P = .001), and higher metastasis rates (48% vs. 33.3%, P < .001) compared to BIDC. Marriage rate was lower in BSCC patients (44.6% vs. 54.9%, P = .009). BSCC patients had worse OS and CSS (P < .001). In non-TNBC, BSCC showed poor survival before and after PSM (P < .05). In TNBC, BSCC had worse OS than BIDC (P < .001), but similar CSS before PSM. After PSM, no survival difference was observed. Stage was a significant prognostic factor for BSCC (P < .001), while receptor subtype was not (P > .05).</p><p><strong>Conclusion: </strong>BSCC has a higher TNBC incidence and poorer survival in non-TNBC populations compared to BIDC. BSCC-TNBC patients have similar survival to BIDC-TNBC. Stage is a crucial prognostic factor for BSCC, more so than receptor subtype.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prognostic Analysis of Hormone Receptors and HER2 in Breast Squamous Cell Carcinoma: A Matched Study Using the SEER Database.\",\"authors\":\"Miao Wang, Kehua Hu, Yanping Gao, Xiaowan Guo, Jie Li, Yaoxiong Xia, Hui Qiu, Qiuji Wu\",\"doi\":\"10.1016/j.clbc.2025.04.015\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To determine the prognostic differences between breast squamous cell carcinoma (BSCC) and breast infiltrating ductal adenocarcinoma (BIDC) by receptor subtype.</p><p><strong>Materials and methods: </strong>We extracted data from the SEER Registry for adult women diagnosed with BSCC and BIDC from 2010 to 2020. Kaplan-Meier curves and log-rank tests assessed survival differences. Propensity score matching analysis (PSM) was used to match subjects with similar characteristics. Cox proportional hazard regression models identified survival predictors.</p><p><strong>Results: </strong>BSCC patients were older (> 60 years: 60.6% vs. 52.4%, P = .037), had higher TNBC incidence (64.0% vs. 12.2%, P = .001), and higher metastasis rates (48% vs. 33.3%, P < .001) compared to BIDC. Marriage rate was lower in BSCC patients (44.6% vs. 54.9%, P = .009). BSCC patients had worse OS and CSS (P < .001). In non-TNBC, BSCC showed poor survival before and after PSM (P < .05). In TNBC, BSCC had worse OS than BIDC (P < .001), but similar CSS before PSM. After PSM, no survival difference was observed. Stage was a significant prognostic factor for BSCC (P < .001), while receptor subtype was not (P > .05).</p><p><strong>Conclusion: </strong>BSCC has a higher TNBC incidence and poorer survival in non-TNBC populations compared to BIDC. BSCC-TNBC patients have similar survival to BIDC-TNBC. Stage is a crucial prognostic factor for BSCC, more so than receptor subtype.</p>\",\"PeriodicalId\":10197,\"journal\":{\"name\":\"Clinical breast cancer\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-05-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical breast cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.clbc.2025.04.015\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical breast cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clbc.2025.04.015","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Prognostic Analysis of Hormone Receptors and HER2 in Breast Squamous Cell Carcinoma: A Matched Study Using the SEER Database.
Objective: To determine the prognostic differences between breast squamous cell carcinoma (BSCC) and breast infiltrating ductal adenocarcinoma (BIDC) by receptor subtype.
Materials and methods: We extracted data from the SEER Registry for adult women diagnosed with BSCC and BIDC from 2010 to 2020. Kaplan-Meier curves and log-rank tests assessed survival differences. Propensity score matching analysis (PSM) was used to match subjects with similar characteristics. Cox proportional hazard regression models identified survival predictors.
Results: BSCC patients were older (> 60 years: 60.6% vs. 52.4%, P = .037), had higher TNBC incidence (64.0% vs. 12.2%, P = .001), and higher metastasis rates (48% vs. 33.3%, P < .001) compared to BIDC. Marriage rate was lower in BSCC patients (44.6% vs. 54.9%, P = .009). BSCC patients had worse OS and CSS (P < .001). In non-TNBC, BSCC showed poor survival before and after PSM (P < .05). In TNBC, BSCC had worse OS than BIDC (P < .001), but similar CSS before PSM. After PSM, no survival difference was observed. Stage was a significant prognostic factor for BSCC (P < .001), while receptor subtype was not (P > .05).
Conclusion: BSCC has a higher TNBC incidence and poorer survival in non-TNBC populations compared to BIDC. BSCC-TNBC patients have similar survival to BIDC-TNBC. Stage is a crucial prognostic factor for BSCC, more so than receptor subtype.
期刊介绍：
Clinical Breast Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of breast cancer. Clinical Breast Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of breast cancer. The main emphasis is on recent scientific developments in all areas related to breast cancer. Specific areas of interest include clinical research reports from various therapeutic modalities, cancer genetics, drug sensitivity and resistance, novel imaging, tumor genomics, biomarkers, and chemoprevention strategies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
